🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Rationale: DCC-2036 is a potent broad spectrum inhibitor of BCR-ABL kinase....
Status
Completed
Location
City of Hope
Start Date
2009-03
Trial ID
NCT00827138
Treatments Being Tested
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036)...
Status
Terminated
Location
University of Alabama Comprehensive Cancer Center
Start Date
2018-10-25
Trial ID
NCT03601897
Treatments Being Tested
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036)...
Status
Terminated
Location
University of California San Francisco (UCSF)
Start Date
2019-01-02
Trial ID
NCT03717415
Treatments Being Tested
The purpose of this study is to determine the safety and tolerability of re...
Status
Terminated
Location
Montefiore Medical Center
Start Date
2016-07
Trial ID
NCT02824575
Treatments Being Tested